India
2 views

OpenAI’s former exec disagrees with Amodei on most things, but backs his AI cancer view

Fidji Simo concurs with Dario Amodei on the crucial need for AI companies to demonstrate genuine medical advancements. It's essential for these enterprises to show tangible outcomes rather than relying solely on…

OpenAI’s former exec disagrees with Amodei on most things, but backs his AI cancer view

Fidji Simo concurs with Dario Amodei on the crucial need for AI companies to demonstrate genuine medical advancements. It's essential for these enterprises to show tangible outcomes.

Fidji Simo concurs with Dario Amodei on the crucial need for AI companies to demonstrate genuine medical advancements. It's essential for these enterprises to show tangible outcomes rather than relying solely on marketing strategies. Simo identifies biological data as a critical hurdle in developing AI-based treatments, particularly noting that cancer research benefits from vast pre-existing datasets. Establishing the needed infrastructure is vital for translating AI intelligence into effective medical solutions.

Times of India Verified Source

Syndicated via official news feed

Explore all India stories

Syndicated feed content with full publisher credit.

India Desk

More in India

Continue reading verified coverage and related developments on this desk.

View All

More from India

Latest developments and reports from the desk

All stories →